Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 251-261

  Guo, Shuling ^a   Booten, Sheri L ^a   Aghajan, Mariam ^a   Hung, Gene ^a   Zhao, Chenguang ^a   Blomenkamp, Keith ^b   Gattis, Danielle ^a   Watt, Andrew ^a   Freier, Susan M ^a   Teckman, Jeffery H ^b   McCaleb, Michael L ^a   Monia, Brett P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE TARGETING; HUMAN; HUMAN CELL; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LONG TERM CARE; MACACA FASCICULARIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; RHESUS MONKEY; SHORT COURSE THERAPY; SYSTEMIC THERAPY; TRANSGENIC MOUSE;

EID: 84892936309     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67968     Document Type: Article

References (62)

1. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of alpha1-Antitrypsin and its role in health and disease. Respir Med. 2011;105(8):1129-1139
2. Ekeowa UI, et al. Á1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. Clin Sci (Lond). 2009;116(12):837-850
3. Greene CM, et al. Á-1 Antitrypsin deficiency: a conformational disease associated with lung and liver manifestations. J Inherit Metab Dis. 2008;31(1):21-34
4. Bals R. Á-1-Antitrypsin deficiency. Best Pract Res Clin Gastroenterol. 2010;24(5):629-633
5. Teckman JH, Lindblad D. Á-1-Antitrypsin deficiency: diagnosis, pathophysiology, and management. Curr Gastroenterol Rep. 2006;8(1):14-20
6. Silverman EK, Sandhaus RA. Clinical practice. Á1-Antitrypsin deficiency. N Engl J Med. 2009; 360(26):2749-2757
7. Fregonese L, Stolk J. Hereditary á-1-Antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16
8. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in á-1-Antitrypsin deficiency: molecular and cellular insights. Eur Respir J. 2009;34(2):475-488
9. Hogarth DK, Rachelefsky G. Screening and familial testing of patients for á-1-Antitrypsin deficiency. Chest. 2008;133(4):981-988
10. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z á-1-Antitrypsin accumulation in the liver. Nature. 1992;357(6379):605-607
11. Ekeowa UI, et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci U S A. 2010;107(40):17146-17151
12. Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with á-1-Antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol. 2012;10(6):575-580
13. Fairbanks KD, Tavill AS. Liver disease in á-1-Antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103(8):2136-2141
14. Esquivel CO, et al. Indications for pediatric liver transplantation. J Pediatr. 1987;111(6 pt 2):1039-1045
15. Carlson JA, et al. Accumulation of PiZ á-1-Antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989;83(4):1183-1190
16. Ali R, et al. Evaluation of a transgenic mouse model for á-1-Antitrypsin (AAT) related liver disease. Ann Hum Genet. 1994;58(pt 4):305-320
17. Ruther U, Tripodi M, Cortese R, Wagner EF. The human á-1- Antitrypsin gene is efficiently expressed from two tissue-specific promotors in transgenic mice. Nucleic Acids Res. 1987;15(18):7519-7529
18. Dycaico MJ, et al. Neonatal hepatitis induced by á-1-Antitrypsin: a transgenic mouse model. Science. 1988;242(4884):1409-1412
19. Sifers RN, Carlson JA, Clift SM, DeMayo FJ, Bullock DW, Woo SL. Tissue specific expression of the human á-1-Antitrypsin gene in transgenic mice. Nucleic Acids Res. 1987;15(4):1459-1475
20. Sifers RN, Finegold MJ, Woo SL. Á-1-Antitrypsin deficiency: accumulation or degradation of mutant variants within the hepatic endoplasmic reticulum. Am J Respir Cell Mol Biol. 1989;1(5):341-345
21. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, á-1-Antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996; 271(37):22791-22795
22. Teckman JH, Perlmutter DH. The endoplasmic reticulum degradation pathway for mutant secretory proteins á-1-Antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem. 1996;271(22):13215-13220
23. Teckman JH, Perlmutter DH. Retention of mutant á(1)-Antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol. 2000;279(5):G961-G974
24. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant á-1-Antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-Antitrypsin deficiency. Proc Natl Acad Sci U S A. 1994;91(19):9014-9018
25. Lindblad D, Blomenkamp K, Teckman J. Á-1-Antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology. 2007;46(4):1228-1235
26. Marcus NY, et al. Characteristics of hepatocellular carcinoma in a murine model of á-1-Antitrypsin deficiency. Hepatol Res. 2010;40(6):641-653
27. Rudnick DA, Perlmutter DH. Á-1-Antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology. 2005;42(3):514-521
28. Perlmutter DH, Silverman GA. Hepatic fibrosis and carcinogenesis in alpha1-Antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb Perspect Biol. 2011;3(3).pii: a005801
29. Hidvegi T, et al. An autophagy-enhancing drug promotes degradation of mutant á-1-Antitrypsin Z and reduces hepatic fibrosis. Science. 2010; 329(5988):229-232
30. Mencin A, et al. Á-1 Antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology. 2007;46(5):1443-1452
31. Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of á-1-Antitrypsin deficiency. Hepatology. 2004;39(4):1048-1055
32. Teckman JH, An JK, Loethen S, Perlmutter DH. Fasting in á-1-Antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy. Am J Physiol Gastrointest Liver Physiol. 2002;283(5):G1156-G1165
33. Rudnick DA, Shikapwashya O, Blomenkamp K, Teckman JH. Indomethacin increases liver damage in a murine model of liver injury from á-1-Antitrypsin deficiency. Hepatology. 2006;44(4):976-982
34. Cruz PE, et al. In vivo post-transcriptional gene silencing of á-1 antitrypsin by adeno-Associated virus vectors expressing siRNA. Lab Invest. 2007; 87(9):893-902
35. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-293
36. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of á-1-Antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther. 2011;5:391-405
37. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992;267(28):19954-19962
38. Monia BP, et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A. 1996;93(26):15481-15484
39. An JK, Blomenkamp K, Lindblad D, Teckman JH. Quantitative isolation of álAT mutant Z protein polymers from human and mouse livers and the effect of heat. Hepatology. 2005;41(1):160-167
40. Crooke RM, Graham MJ. Suborgan pharmacokinetics. In: Stanley TC, ed. Antisense Drug Technology: Principles, Strategies, and Applications. New York, New York, USA: Marcel Dekker; 2001:155-182
41. Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011;39(11):4795-4807
42. Stoller JK, Fromer L, Brantly M, Stocks J, Strange C. Primary care diagnosis of á-1 antitrypsin deficiency: issues and opportunities. Cleve Clin J Med. 2007;74(12):869-874
43. Lomas DA. The selective advantage of á-1-Antitrypsin deficiency. Am J Respir Crit Care Med. 2006; 173(10):1072-1077
44. Sveger T. The natural history of liver disease in á 1-Antitrypsin deficient children. Acta Paediatr Scand. 1988;77(6):847-851
45. Eriksson S. Á 1-Antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. Acta Med Scand. 1987;221(5):461-467
46. Clark VC, Dhanasekaran R, Brantly M, Rouhani F, Schreck P, Nelson DR. Liver test results do not identify liver disease in adults with á(1)-Antitrypsin deficiency. Clin Gastroenterol Hepatol. 2012; 10(11):1278-1283
47. Bowlus CL, et al. Factors associated with advanced liver disease in adults with á1-Antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005; 3(4):390-396
48. Hidvegi T, Mukherjee A, Ewing M, Kemp C, Perlmutter DH. The role of autophagy in á-1-Antitrypsin deficiency. Methods Enzymol. 2011;499:33-54
49. Marciniak SJ, Lomas DA. Á1-Antitrypsin deficiency and autophagy. N Engl J Med. 2010; 363(19):1863-1864
50. Yusa K, et al. Targeted gene correction of á1-Antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011;478(7369):391-394
51. Mueller C, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. 2012;20(3):590-600
52. Alam S, Wang J, Janciauskiene S, Mahadeva R. Preventing and reversing the cellular consequences of Z á-1 antitrypsin accumulation by targeting s4A. J Hepatol. 2012;57(1):116-124
53. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant á 1-Antitrypsin (á 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in á 1-AT deficiency. Proc Natl Acad Sci U S A. 2000;97(4):1796-1801
54. Raal FJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006
55. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76(2):269-276
56. Lomas DA, Evans DL, Stone SR, Chang WS, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of á 1-Antitrypsin. Biochemistry. 1993;32(2):500-508
57. Mahadeva R, et al. Polymers of Z á1-Antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol. 2005;166(2):377-386
58. Fregonese L, Stolk J, Frants RR, Veldhuisen B. Á-1 Antitrypsin Null mutations and severity of emphysema. Respir Med. 2008;102(6):876-884
59. Carroll JB, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178-2185
60. Yu D, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012;150(5):895-908
61. Quistorff B, Dich J, Grunnet N. Preparation of isolated rat liver hepatocytes. Methods Mol Biol. 1990;5:151-160
62. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 1981;112(1):70-75.